一项测试 Survodutide 是否可以改善肥胖症患者身体利用能量和分解脂肪的方式的研究
一项主动比较器控制、开放标签、平行组研究,旨在评估 Survodutide 对肥胖受试者能量消耗和脂肪酸氧化的影响
This study is open to adults between 18 and 65 years of age who have obesity. People can join the study if they have a body mass index (BMI) between 30 and 45 km/m². The purpose of this study is to find out whether a medicine called survodutide improves how the body uses energy and breaks down fat. This study compares survodutide with another medicine called semaglutide. Survodutide is being developed to treat people with obesity.
Semaglutide is already used to treat people with obesity.
Participants are put into 2 groups by chance. One group gets survodutide and the other group gets semaglutide. Participants get survodutide or semaglutide as an injection under the skin once a week. Participants are in the study for 8-10 months depending on how long the treatment is given. During this time, they visit the study site weekly. Some of the visits may also be done at the participant's home instead of the study site.
At some of the visits, doctors test how much energy a participant's body uses. This is done in a special room where they measure the oxygen that is breathed in and the carbon dioxide that is breathed out by the participant. The results are compared between the 2 groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.
研究概览
研究类型
注册 (实际的)
阶段
- 阶段1
联系人和位置
学习地点
-
-
Florida
-
Orlando、Florida、美国、32804
- AdventHealth - Translation Research Institute
-
-
Louisiana
-
Baton Rouge、Louisiana、美国、70808
- Pennington Biomedical Research Center
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion criteria
-
Age of 18 to 65 years (inclusive)
-
Male or female subjects with obesity (defined as a body mass index (BMI) of ≥30 and ≤45 kg/m²)
-
Woman of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of use is provided in the participant information
-
Signed and dated written informed consent in accordance with International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use - Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
-
In the investigator's opinion, are well-motivated, capable, and willing to:
- Learn how to self-inject the investigational medicinal product (IMP), as required for this protocol (persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject the IMP)
- Inject the IMP or accept injection from a designated person --- Follow trial procedures for the duration of the trial, including, but not limited to: follow lifestyle advice (for example, dietary restrictions and exercise, maintain a diary, complete required questionnaires, and handle the IMP as described in the instruction for use (IFU))
Exclusion criteria:
- Current or history of significant alcohol consumption (defined as intake of >210 g/week in men and >140 g/week in women on average over a consecutive period of more than 3 months) or are unwilling to stop alcohol consumption 48 h before admission to the research facility and until discharge
- History of chronic liver disease / cirrhosis
- Body weight variation (self-reported) >5% within 3 months before Visit 1 (screening)
- Medications for obesity (including over-the-counter medications) within 3 months before Visit 1 (screening)
- Glycated haemoglobin (HbA1c) ≥6.5% (≥48 mmol/mol) as measured by the local laboratory at screening
- History of type 1 diabetes mellitus (T1DM) or T2DM or treatment with glucose lowering agent started within 3 months before Visit 1 (screening) Further exclusion criteria apply.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:残余肽臂
|
Survodutide
其他名称:
|
|
有源比较器:索马鲁肽臂
|
Semaglutide
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
从基线到第一次拜访的睡眠代谢率(SMR)的绝对变化(SMR)(以整个房间量热计测量)至少达到10%的体重减轻
大体时间:在基线时,长达36周
|
在基线时,长达36周
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
从基线到第一次访问的SMR的相对变化(在整个房间量热计中测量)至少达到10%的体重减轻
大体时间:在基线时,长达36周
|
在基线时,长达36周
|
|
从基线到首次访问的睡眠期间脂肪酸氧化的绝对变化(在整个房间量热计)中至少达到10%的体重减轻
大体时间:在基线时,长达36周
|
在基线时,长达36周
|
|
从基线到第一次访问的睡眠期间脂肪酸氧化的相对变化(在整个房间量热计)中至少达到了至少10%的体重减轻
大体时间:在基线时,长达36周
|
在基线时,长达36周
|
合作者和调查者
出版物和有用的链接
有用的网址
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 1404-0045
- U1111-1309-3679 (注册表标识符:WHO register - International Clinical Trials Registry Platform (ICTRP))
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement".
Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
IPD 共享时间框架
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
IPD 共享访问标准
For study documents - upon signing of a "Document Sharing Agreement". For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
IPD 共享支持信息类型
- 研究方案
- 树液
- 企业社会责任
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.